PSMA PET scan for prostate cancer: when it is used, what it costs, and what the result means

How a PSMA PET scan works

The tracer contains a molecule that binds to PSMA and a small amount of radioactive material. After the tracer is injected, the scanner detects where it accumulates and creates a map of uptake across much of the body.

PSMA is commonly present on prostate cancer cells, but it is not exclusive to them. Normal salivary glands, kidneys, liver, spleen, bowel, and other tissues may show expected activity. The radiologist distinguishes expected uptake from findings that need attention.

Who may need the scan—and who may not

A PSMA PET scan may be considered when newly diagnosed cancer has a meaningful risk of spread, when PSA rises after surgery or radiation and recurrence is suspected, or when PSMA-targeted treatment is being evaluated. The exact indication depends on pathology, PSA, prior treatment, symptoms, and the decision ahead.

Most people with cancer confined to the prostate do not automatically need this test. Availability and insurance rules also vary. Ask why PSMA PET is preferred over—or added to—MRI, CT, a bone scan, or another PET tracer in your situation.

Is there a PSA level that automatically triggers PSMA PET?

No universal PSA threshold applies to every patient. After treatment, the likelihood of detecting recurrent disease generally changes with the PSA level and its pattern, but the decision also depends on the original cancer risk, treatment received, symptoms, timing, and whether finding a small site of disease would change management.

Ask the ordering clinician what a positive, negative, or indeterminate result would change. A scan should answer a management question, not simply produce more information.

What to expect before and during the scan

Follow the imaging center's instructions. You may be asked to hydrate, review medicines and allergies, remove metal, and report claustrophobia or implanted devices. Do not assume instructions for another PET scan or MRI apply to this tracer.

Mayo Clinic describes a process that commonly takes about two to three hours, including injection, an uptake period, and roughly 30 to 60 minutes in the scanner. The exact tracer, wait time, body coverage, and use of CT or MRI can differ by center.

How to read the report with your clinician

The report may name the tracer, describe the PET and accompanying CT or MRI, list sites of expected and unexpected uptake, and end with an impression. The intensity of a spot alone does not determine stage or treatment.

Ask whether each finding is in the prostate or prostate bed, lymph nodes, bone, or another organ; whether it is definite, suspicious, indeterminate, or likely benign; and whether comparison with prior imaging changes the interpretation.

False negatives, false positives, and incidental findings

A false-negative result can occur when cancer expresses little PSMA, a deposit is too small to resolve, or expected activity in nearby organs obscures it. A negative scan does not erase an established tissue diagnosis or every possibility of microscopic disease.

False-positive or incidental uptake can occur in benign conditions and, rarely, other cancers. Additional imaging, follow-up, or biopsy may be needed before a finding changes treatment.

Radiation, reactions, cost, and aftercare

PSMA PET exposes the body to ionizing radiation from the tracer and often from the CT portion. Injection-site discomfort or an allergic reaction is possible but uncommon. The imaging team weighs the exposure against the expected diagnostic benefit.

Confirm prior authorization, the tracer and facility covered, estimated patient cost, and whether the interpretation is in network. After the scan, follow the center's hydration, bathroom, travel, pregnancy-contact, and medication instructions rather than using a generic online rule.

What a PSMA PET scan costs in 2026, by site of service

There is no single national price, so start with the one public benchmark that is updated every year. Medicare's Procedure Price Lookup for CPT code 78815, the PET/CT code most PSMA studies are billed under, lists as of September 2026 a national average Medicare-approved amount of $1,569 in a hospital outpatient department ($1,460 facility fee plus a $109 physician fee), with Medicare paying $1,255 and the patient paying about $313. In a non-hospital setting the same code averages $893 ($784 facility plus $109 physician), with Medicare paying $714 and the patient paying about $178. Those figures cover the scan and the read; the tracer is billed under its own code.

Cash prices sit well above the Medicare rate because the tracer is priced separately by its manufacturer. PET Imaging of Florida, a freestanding center, posts a standard $1,000 charge for the scan portion plus a tracer cost it describes as approximately $5,000. GoodRx reports that a PSMA PET scan can cost about $4,500 out of pocket and that some facilities give a discount to people without insurance. A 2023 analysis by Holzgreve and colleagues in the European Journal of Nuclear Medicine and Molecular Imaging modeled a U.S. PSMA PET/CT reimbursement of $5,438 (range $4,350 to $6,526) against $2,161 for conventional imaging.

Billed charges at hospitals and academic centers can be far higher than what any payer allows. In a January 2025 Mayo Clinic Connect thread, one member reported a $21,500 total charge with $2,771 patient responsibility after a private plan approved the scan, and another reported a $22,790 charge reduced to a $5,503 allowed amount with a $365 copay, plus a separate $4,164 line the member believed was the tracer. Those are individual reports, not price lists, but they show why the allowed amount and your cost sharing matter more than the sticker charge.

Why two PSMA PET bills can differ by thousands of dollars

The tracer is the largest variable. The Novitas Solutions billing article that governs New Jersey Medicare claims lists five tracers, each billed under its own HCPCS code: Pylarify (A9595), Illuccix (A9596), Posluma (A9608), Locametz (A9800), and Gozellix (A9616). Manufacturers set tracer prices, and PET Imaging of Florida's posted cash split makes the effect explicit: about $5,000 for the tracer against $1,000 for the scan.

The facility fee changes with the setting. Medicare's Procedure Price Lookup shows the same $109 physician fee in both settings but a $1,460 facility fee in a hospital outpatient department against $784 elsewhere, which is why the average patient share is $313 versus $178. In hospital outpatient departments Medicare pays a diagnostic radiopharmaceutical separately only when its per-day cost exceeds a packaging threshold, which the CY 2026 Outpatient Prospective Payment System final rule raised from $630 to $655 according to Holland & Knight's summary of the rule; tracers priced in the thousands clear that line and appear as their own payment line rather than being folded into the scan.

The imaging protocol and the read are separate questions. CPT 78815 already includes a CT acquired for attenuation correction and anatomical localization from skull base to mid-thigh, 78816 is the whole-body PET/CT code, and 78812 and 78813 are the PET-only codes, as listed on Telix's Illuccix coding page. Ask whether the center uses PET/CT or PET/MRI, whether any separate diagnostic CT or MRI is planned, and whether the facility, the radiologist reading the study, and the tracer supplier are all in your network; each answer can change what appears on the bill and what the plan allows.

Does Medicare cover a PSMA PET scan? Part B rules as of September 2026

Original Medicare covers PSMA PET under Part B through regional contractor rules rather than one national policy. CMS's national coverage determination 220.6 for PET scans provided that, effective for dates of service on or after March 7, 2013, local Medicare Administrative Contractors may determine coverage for PET using radiopharmaceuticals for their FDA-approved labeled indications for oncologic imaging, and CMS removed that umbrella determination on January 1, 2022, leaving coverage with the contractors. New Jersey's contractor, Novitas Solutions, publishes a billing article (last modified February 25, 2026) covering PSMA PET for men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, for suspected recurrence based on elevated serum PSA levels, and, for Locametz and Illuccix only, for selection of patients for a PSMA-directed radioligand therapy.

What you pay under Original Medicare follows the Part B formula. As of September 2026 the Part B deductible is $283, after which you usually pay 20% of the Medicare-approved amount for each covered service or item, according to Medicare.gov. In a hospital outpatient setting you also pay a copayment to the hospital for each service, which in most cases will not be more than the Part A hospital stay deductible of $1,736. The Procedure Price Lookup figures above ($313 in a hospital outpatient department, $178 elsewhere for the scan code) are national averages of that patient share, and the separately billed tracer is a covered item subject to the same cost-sharing rules.

Supplemental coverage decides the final number. Medicare.gov describes Medigap as extra insurance you can buy from a private company to help pay your share of Original Medicare costs such as copayments, coinsurance, and deductibles, and notes that Original Medicare has no yearly limit on what you pay out of pocket unless you have supplemental coverage. Medicare Advantage plans set their own cost sharing, have a yearly out-of-pocket limit, may require approval (prior authorization) before covering certain services, and cannot be combined with Medigap; the Procedure Price Lookup tells Medicare Advantage members to talk to their plan about costs.

Medicare does not publish a fixed number of PSMA PET scans per year. The one-initial and three-subsequent scan limits many readers find online come from NCD 220.6.17, which governs FDG PET for oncologic conditions, a different tracer. The Novitas article contains no frequency limit; each scan must match a covered indication, the tracer code must be billed for the same date of service as the scan or the claim rejects, and the claim carries the PI modifier for initial treatment strategy or the PS modifier for subsequent treatment strategy.

Private insurance, prior authorization, and how to appeal a denial

Commercial plans decide by policy, and prior authorization is the step that most often stalls a scan. PET Imaging of Florida notes that after CMS created dedicated PSMA tracer billing codes in 2022, third-party insurers often followed Medicare and added the tracers to their formularies, but each plan still reviews the indication for the individual request. Ask the ordering office to submit the diagnosis, PSA history, pathology, prior treatment, and the planned tracer and CPT code, and to record the authorization number, the approved site of service, and the approval window before the appointment.

Manufacturer reimbursement programs help the office with paperwork; they do not pay the bill. Telix's Illuccix Reimbursement Support (1-844-458-3549) performs benefit investigations, assists with prior authorization and with appealing denied claims, and provides payer coverage policies. Lantheus Link (1-800-362-2668) offers reimbursement and payer specialists for Pylarify insurance coverage, billing and coding, and prior authorization questions. Blue Earth Diagnostics assigns field reimbursement managers for Posluma who support prior authorizations, appeals, denials, and the peer-to-peer process, and Novartis Patient Support provides insurance and coding support for Locametz. Telix, Blue Earth, and Novartis each state on those pages that billing codes do not guarantee coverage or payment.

If a private plan denies the scan, HealthCare.gov sets the clock. You must file an internal appeal within 180 days of receiving the denial notice; the plan must complete the appeal within 30 days for a service you have not yet received, within 60 days for a service already received, and at least within 4 business days when the case is urgent. Keep the Explanation of Benefits, a copy of the appeal request, any letter from your doctor, and dated notes of every call. If the internal appeal fails and the denial involves medical judgment or a claim that the scan is experimental, you can request an external review within 4 months of the final denial; standard reviews are decided no later than 45 days after the request, expedited reviews within 72 hours, and your insurer is required by law to accept the external reviewer's decision.

Medicare denials follow a different path. In Original Medicare, file by the date printed on your Medicare Summary Notice, using the Redetermination Request Form or a written request to the Medicare Administrative Contractor (Novitas in New Jersey); you will generally get a decision within 60 days after they receive the appeal. In a Medicare Advantage plan, you, your representative, or your doctor must file within 65 days of the date on the denial notice; the plan has 30 days for a pre-service appeal, 60 days for a payment appeal, and 72 hours for a fast appeal, and if it decides against you the case is automatically sent to level 2 review.

Paying cash, Good Faith Estimates, and financial assistance

If you are uninsured or choose not to use insurance, federal rules entitle you to a written Good Faith Estimate. CMS explains that a provider must give one when you ask or when you schedule at least 3 business days ahead: within 1 business day if the appointment is 3 to 9 days out, and within 3 business days if it is 10 or more days out. Keep it, because the estimate is what you need to dispute a final bill, and the No Surprises Help Desk (1-800-985-3059) handles questions about that process.

Hospitals must also post prices. Since January 1, 2021, CMS has required each hospital to provide clear, accessible pricing information online as a comprehensive machine-readable file of all items and services and as a consumer-friendly display of shoppable services, and the CY 2026 rule adds median, 10th percentile, and 90th percentile allowed amounts to that file starting January 1, 2026. Ask the hospital billing office for its cash price for CPT 78815 and for the tracer's HCPCS code, and compare it with your Good Faith Estimate.

Nonprofit hospitals must maintain a written financial assistance policy. Under Internal Revenue Code section 501(r)(4), a hospital organization must establish a written policy that states who is eligible, how amounts charged are calculated, how to apply, and what happens if a bill goes unpaid, and it must post the complete policy and a plain-language summary on its website. If a hospital outpatient department is the only PSMA PET site available to you, ask for that policy before the scan rather than after the bill.

Manufacturer programs may help with cost, but none of the pages reviewed for this guide publishes a fixed patient discount. Lantheus Link offers personalized guidance on financial assistance programs that may be available, including foundation assistance options, for Pylarify. GoodRx notes that some facilities give a discount to people without insurance, and PET Imaging of Florida states that the exact cash cost is provided beforehand with no hidden fees. Ask each candidate center for its self-pay price in writing before choosing where to have the scan.

PSMA PET billing codes to ask for on the estimate

An estimate is only comparable when it names the codes. The scan is billed under a CPT code and the tracer under a separate HCPCS Level II code, and Novitas warns that PET scan claims reject if a tracer code is not billed for the same date of service, and vice versa. Medicare claims also carry the PI modifier for initial treatment strategy or the PS modifier for subsequent treatment strategy; the KX modifier is not required.

The tracer decides the code, the price, and sometimes the coverage decision. The FDA approved the first PSMA-targeted PET drug, Ga 68 PSMA-11, on December 1, 2020, and Pylarify on May 27, 2021; Urology Times records Illuccix's approval in December 2021 and Gozellix's in March 2025, and Blue Earth Diagnostics lists Posluma's HCPCS code as effective January 1, 2024. Ask which tracer the center will actually use on the day, not only which ones it stocks.

Turn the result into one documented next step

Ask who will review the scan with you, when that conversation will happen, and whether the finding changes stage, radiation fields, surgery planning, systemic treatment, biopsy, or surveillance. If the scan is negative or unclear, ask what evidence still drives the plan.

Keep the report, images or image-access instructions, tracer name, scan date, current PSA and pathology summary together. That package makes a second opinion or multidisciplinary review more useful.